

**Press Release**  
**For immediate release**



**genoway launches standardized genetically modified mouse and rat research models**

**The biotechnology company continues its strong growth (+50% tendency) and reinforces its international leadership in the development and supply of genetically modified animal models. The products henceforth available from the catalogue have already attracted Pfizer, GSK, BMS and Servier.**

**Lyon (France), 19 November 2007** - genOway, a biotechnology company specialized in the development of genetically modified research models for the biopharmaceutical industry today announces today the launching of its catalogue activity, based on the development and supply of standardized tools.

This offer of animal models developed by genOway's R&D teams or via the acquisition of exclusive and non-exclusive licenses from prestigious academic laboratories such as Yale University (Connecticut), the Hubrecht Institute (Netherlands), and the University of Michigan is based on the supply of ready-for-use tools selectable from the catalogue.

The biological profile of these new animal models offers numerous advantages for biomedical researchers: rapid availability, acquisition of biological predictability of the effects on the human organism and a shortening the development cycle of the therapeutic solutions.

To date, genOway has elaborated a catalogue of standardized products - of which the company retains the entire of intellectual property - spanning four major therapeutic axes:

- Inflammatory and metabolic pathologies (diabetes, obesity)
- Diseases of the central nervous system (depression, anxiety)
- Infectious diseases and allergy
- Gastroenterology.

In the area of metabolic illnesses, this offer has already attracted many major players in the biopharmaceutical industry, such as Pfizer, GlaxoSmithKline, Bristol-Myers Squib and Servier. genOway registered in mid-November 2007 an order sheet of over 0.8 million euros in this domain.

Alexandre Fraichard, CEO of genOway, stated : "We are delighted to observe the success achieved by our catalogue models. Recognition by many major pharmaceutical companies validates our choices and our technical platform. Moreover, genOway benefits from privileged links with the most cutting edge academic teams at international level, which grant us exclusive and non-exclusive licenses on the animal models which we judge

pertinent. Thus our catalogue of standardized products will become richer in the coming months with new proprietary models. We intend to continue our proactive license acquisition policy, and have other licenses currently in negotiation”.

Kader Thiam, VP Transgenic Technologies at genOway added: “Through this new commercial offer, genOway can now offer two distinct responses to the same demand from industrial clients. The latter can now choose between customized development of genetically modified animal models and the acquisition of standardized and more rapidly available animal models. This approach reinforces our image as the reference point supplier for the entirety of biomedical research”.

To date, genOway makes its expertise available to over 40 major biopharmaceutical groups and 160 academic institutions, either through customized development of genetically modified research animal models or through its emerging activity of sale of proprietary models.

### **About genOway:**

genOway (ALTERNEXT-NYSE:ALGEN) is a biotechnology company dedicated to the development of genetically modified animal models aimed at enhancing the security and relevancy of in vivo research projects. Focusing its efforts on the mouse and rat, genOway's expertise combined transgenic technologies such as pronuclear microinjection, Knock-out, Knock-in, Knock-down, point mutation, humanization combined with innovative patented technologies adapted to target validation, in vivo drug screening, drug efficacy and safety testing program. Collaborations with worldwide leaders (Charles River Laboratories, Invitrogen, Tet systems, etc..) enable genOway to provide its customer with a complete portfolio of products and services for all aspects of model generation and characterization. Operating in 22 countries in Europe, North America and Asia, genOway has developed more than 450 rat and mouse lines for 40 companies and 160 research institutions. Thanks to its industrialized production facilities, genOway is involved in large-scale projects with several academic centers (German National Genome Research Network, University College London, King's College London, Max Planck Institute) and with pharmaceutical companies (Bayer Corp, Boehringer Ingelheim, Johnson & Johnson).

For more information consult: [www.genoway.com](http://www.genoway.com)

### **Contacts:**

Marie Norbert - genOway - [norbert@genoway.com](mailto:norbert@genoway.com)

Contact for investors:

Gilles de Poncins, CFO - genOway - [finances@genoway.com](mailto:finances@genoway.com)

Milestones - Press & Investors Relation

Bruno Arabian

Tel. : +33 170 08 04 13

E-mail : [milestones@milestones-fr.com](mailto:milestones@milestones-fr.com)

Warning: This press release expressly contains, in an implicit manner, certain prospective statements concerning genOway and its activity. These statements rely on certain risks, known or unknown, uncertainty or on other factors that may lead to actual results, financial conditions, performance or achievements on the part of genOway that may differ significantly from the results, financial conditions, performance or achievements expressed or implied in these prospective statements. genOway is issuing this press release on the present date and is not committed to update the prospective statements contained therein, either as a result of new information, future events or other. For a description of the risks or uncertainty of

a nature to cause a difference between genOway's actual results, financial conditions, performance or achievements and those contained in the prospective statements, please refer to the section on "Risk Factors" on the Prospectus available on the genOway website:  
<http://www.genoway.com>